ImmBioVax™ vaccines are pathogen-derived multi-component products isolated from cells stressed to mimic the natural response to infection. ImmBio is developing ImmBioVax™ vaccines against a number of targets, including invasive meningococcal disease, tuberculosis and invasive pneumococcal disease. The vaccines incorporate multi-protein complexes to elicit broad priming of the immune system to block subsequent infection by multiple pathogen strains.
ImmBioVax™ vaccines target antigens to dendritic cells (DC) to facilitate uptake, cell maturation and antigen presentation. Cell chaperones, a key component of ImmBioVax™ vaccines, bind polypeptide chains to prevent aggregation and support protein folding. Expression of these proteins is increased with stress and they have important immunological functions providing a link between the innate and acquired immune responses.
Cell chaperones induce a number of innate responses, activate DCs, increase surface expression of MHC class II and stimulate secretion of pro-inflammatory cytokines. As chaperones are found complexed to cellular proteins, these multi-protein complexes are capable of delivering antigens to DC.
MoA studies with Prof Phil Sutton at the University of Melbourne, has shown that ImmBioVax™ vaccine induce both antibody and cell mediated immunity via both MyD88 and TRIF dependent pathways. These studies also revealed a previously unknown MyD88 independent pathway of antibody induction.
Additional information on this technology is provided in the publications highlighted.